Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | CHRND | Q07001 | 7/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.53 |
| ▸ | CHRNG | P07510 | 3/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22045372 | 0.83 | GNPAT (0.52) | TLR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25062089 | 0.82 | MMP2 (0.53) | — | |
| SCHEMBL20669101 | 0.81 | OPRK1 (0.61) | TLR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22388988 | 0.80 | GNPAT (0.53) | CALCRL | |
| SCHEMBL25062471 | 0.79 | TLR2 (0.57) | TLR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22030266 | 0.79 | OPRK1 (0.63) | — | |
| SCHEMBL23901052 | 0.78 | MMP2 (0.54) | — | |
| SCHEMBL23106089 | 0.78 | F2 (0.47) | TLR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21788100 | 0.78 | GNPAT (0.50) | CALCRL | |
| Lysine SCHEMBL9441740 | 0.77 | CHRNB2 (0.65) | TLR2CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | TLR2 2113/4885CHRNB2 4071/4885CHRNB4 4248/4885 |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | TLR2 2113/4885CHRNB2 4071/4885CHRNB4 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.